ABOUT US
The landscape of MPN blood cancers is shifting, with emerging treatments and evolving perceptions that are bringing newfound hope to patients, caregivers, and clinicians. Sole 2 Soul for MPN is an innovative collaboration between Canadian MPN Research Foundation and CURE Media Group. We are dedicated to supporting and uplifting the MPN Blood cancer community in both Canada and the USA. We empower those who are closely impacted by MPN blood cancers to challenge their inner adventurer while raising funds to fuel change for those who are facing a debilitating incurable blood cancer.
CURE Media Group’s flagship product, CURE magazine, is the indispensable guide to every stage of the cancer experience. With nearly 1 million readers, CURE is the largest consumer publication in the United States focused entirely on cancer, with broad distribution to cancer patients, cancer centers and advocacy groups. CURE Media Group’s offerings also include its online resource, curetoday.com; live meetings; a resource guide for the newly diagnosed; and the Extraordinary Healer™ national nursing award. CURE Media Group combines science and humanity to make cancer understandable.
SUPPORTING SPONSORS
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. With a focus on delivering transformational therapies for cancer patients GSK’s pipeline includes immuno-oncology, cell therapy, and epigenetics. Our goal is to achieve a sustainable flow of new treatments for cancer patients based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, multi-specific molecules, adjuvants and cells, either alone or in combination. Company values are Patient focus, Transparency, Respect and Integrity.
PharmaEssentia, based in Taipei, Taiwan, is focused on leveraging deep expertise and proven scientific principles to deliver new biologics for challenging diseases in the areas of hematology and oncology. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today the company is expanding its global presence with one approved product and a diversifying pipeline. Learn more about our team and our focus by visiting our website
